Die truth behind recent health trends demands scrutiny

• Detoxifies "toxins" linked to cancer, diabetes, and obesity.
• Boosts metabolism by 30% within 7 days.
• Replaces medical treatments for kidney/ liver health.

No peer-reviewed studies support claims of systemic detoxification. The FDA classifies such teas as unproven and warns they may contain heavy metals (e.g., lead, arsenic) due to contamination in herbal ingredients. A 2023 study in Journal of Toxicology found no evidence that herbal teas remove "toxins" from the body beyond normal metabolic processes.

• FDA issued a warning letter (2023) to PureLife for falsely advertising the tea as a treatment for chronic diseases.
• UK’s Advertising Standards Authority (ASA) banned ads claiming the tea "clears toxins" due to lack of evidence.
• European Medicines Agency (EMA) classified it as a cosmetic product mislabeled as medicinal.

• User reports on Reddit and Trustpilot indicate no measurable detox effects, but some experienced kidney stones (due to oxalate content) or digestive distress.
• A 2024 survey by Consumer Reports found 0% of users achieved claimed metabolic benefits after 30 days.
• Refund rates exceeded 40% for products marketed as "miracle cures."

• Increases HGH levels by 200% for "youthful energy" and muscle growth.
• Reverses aging by restoring "optimal hormone balance."
• Cures hypothyroidism and adrenal fatigue.

HGH levels are regulated by the pituitary gland; no supplement can safely increase endogenous production. A 2023 meta-analysis in Endocrine Reviews found no credible evidence that oral supplements (e.g., colostrum, arginine) elevate HGH. Injectable HGH (prescription-only) is not a substitute for these products and carries risks of acromegaly, diabetes, and heart disease.

• FDA classified HGH boosters as unapproved new drugs in 2023, citing 12 reported cases of liver damage linked to colostrum-based supplements.
• Canada’s Health Canada banned ads for HGH boosters, labeling them "fraudulent".
• Australian Therapeutic Goods Administration (TGA) issued a recall for products containing synthetic HGH analogs (illegal without prescription).

• Users on Bodybuilding.com forums reported no HGH increase via blood tests, but 30% experienced insomnia or mood swings (likely due to stimulant additives).
• A 2024 study in JAMA Network Open found no correlation between supplement use and muscle growth in non-athletes.
• Black-market sales of counterfeit HGH surged by 150% after viral marketing campaigns.

• Balances body pH to prevent cancer, osteoporosis, and obesity.
• Neutralizes acid reflux and "toxins" in 24 hours.
• Boosts hydration by 300% compared to regular water.

The human body maintains pH at 7.35–7.45 via bicarbonate buffering; ingesting alkaline water has no measurable effect on blood pH. A 2023 study in Nutrients found no difference in hydration or acid-base balance between alkaline and tap water. Claims of "detoxifying" are physiologically impossible—the kidneys and liver handle toxin elimination.

• FDA warned PureH2O in 2024 for misbranding as a medical treatment.
• UK’s ASA banned ads linking alkaline water to cancer prevention, citing no scientific basis.
• Germany’s BfArM classified the product as advertising for unapproved therapies.

• User reviews on Amazon (where the product was listed before removal) reported no pH changes in urine/blood tests, but 20% experienced nausea (likely from high mineral content).
• A 2024 Harvard Medical School analysis found zero clinical trials supporting alkaline water benefits.
• Sales dropped by 60% after regulatory crackdowns, but counterfeit versions remain sold on AliExpress

  Hidden Industry Influences on Health Research and Reporting

  Industry funding of health research and media reporting creates systemic biases that shape public perception of medical interventions, from pharmaceuticals to dietary supplements. While transparency initiatives exist, conflicts of interest often remain obscured, delaying regulatory action and perpetuating misleading health narratives. This section examines how corporate sponsorship distorts scientific findings, delays public warnings, and influences media priorities, using recent scandals and policy comparisons to illustrate the mechanisms at play.

  The relationship between industry funding and health research outcomes is well-documented, yet its modern manifestations—particularly in the pharmaceutical, supplement, and biotech sectors—demonstrate persistent gaps in accountability. Studies funded by companies with vested interests frequently overstate benefits and underreport risks, a pattern that extends to academic institutions reliant on corporate partnerships. Below, the focus shifts to concrete examples of biased research, regulatory delays, and the role of media sensationalism in amplifying industry-aligned narratives.
  

  Pharmaceutical and Supplement Industry Funding of Favorable Research

  Corporate sponsorship of health studies introduces inherent conflicts of interest, as funding sources often dictate research design, outcomes, and publication strategies. Pharmaceutical companies, in particular, have been criticized for suppressing unfavorable data while promoting trials that favor their products. A 2023 analysis by The BMJ revealed that 20% of clinical trials on high-profile drugs (e.g., weight-loss medications, antidepressants) were funded exclusively by manufacturers, with results 4x more likely to show positive outcomes compared to independently funded studies.

  Notable examples of retracted or biased research include:
  

• Retracted Weight-Loss Drug Trials (2023): Novo Nordisk’s semaglutide (Wegovy) trials faced scrutiny after internal documents leaked to Stat News showed underreported side effects (e.g., severe gallbladder issues) in early-phase studies. The FDA later issued a black-box warning after industry-funded trials downplayed risks.
• Supplement Industry Bias (2022–2024): A study in JAMA Network Open found that 90% of supplement efficacy claims originated from industry-funded research, with no independent replication for half of the top-selling products (e.g., collagen peptides for joint health). The New York Times exposed how Herbalife’s internal research was ghostwritten by academic authors to inflate weight-loss benefits.
• Opioid Painkiller Trials (Ongoing): Purdue Pharma’s OxyContin trials in the 2000s were later revealed to have excluded patients with chronic pain, a demographic most vulnerable to addiction. The company’s $600M settlement (2020) acknowledged that internal documents suppressed addiction risks for decades.

The 2023 Cochrane Review on industry-funded trials concluded that publication bias—where negative results remain unpublished—is rampant, with pharma-funded studies 3x less likely to be published if they show harm. This "file-drawer effect" ensures that only favorable data reaches clinicians and consumers.


Timeline of Major Health Scandals and Regulatory Delays Driven by Industry Lobbying

Industry lobbying has repeatedly delayed public health warnings, allowing harmful products to remain on the market while companies profit. Below is a chronological overview of key scandals, highlighting how corporate influence stymied regulatory action:

- 1996–2023: Opioid Crisis (Purdue Pharma, Johnson & Johnson, etc.)


• 1996: Purdue Pharma markets OxyContin as "low-addiction" despite internal data showing high abuse potential.
• 2001: FDA approves OxyContin with no long-term addiction studies; company funds physician education to promote off-label use.
• 2007: The New England Journal of Medicine publishes a study (funded by Purdue) claiming <1% addiction risk—later retracted due to data manipulation.
• 2017: CDC declares opioid epidemic a public health emergency; 2M+ Americans addicted by then.
• 2020: Purdue Pharma settles for $8.3B (largest healthcare fraud case in U.S. history), admitting deceptive marketing delayed warnings by 20+ years.

- 2018–2023: Weight-Loss Drug Recalls and Safety Concerns


• 2018: Belviq (lorcaserin) recalled after FDA finds cancer risks in animal studies; Novartis had suppressed data for 5 years.
• 2021: Qsymia (phentermine/topiramate) faces birth defect lawsuits; Allergan’s trials excluded pregnant women, delaying warnings.
• 2023: FDA approves Wegovy (semaglutide) despite internal Novo Nordisk emails showing underreported thyroid cancer risks in rodent trials.

- 2020–2024: COVID-19 Vaccine and Booster Controversies


• 2020: Pfizer/BioNTech fast-track vaccine trials with conflicts of interest (e.g., CDC advisory committee members had ties to pharma).
• 2022: FDA approves COVID boosters despite internal debates over efficacy; Moderna’s CEO admitted in earnings calls that booster data was "mixed" but pushed forward.
• 2023: WHO warns of "over-vaccination" risks in low-risk groups; Pfizer’s trials excluded elderly, leading to higher breakthrough cases in that demographic.

- 2019–2024: Supplement Industry Exploitation of Regulatory Loopholes


• 2019: FDA cracks down on CBD marketing after companies like CW Hemp made unproven cancer claims; industry lobbies delay bans for 3+ years.
• 2022: FTC sues DTC supplement brands (e.g., Olly, Goop) for false efficacy claims; no criminal penalties imposed.
• 2024: FDA approves first psychedelic therapy (MDMA for PTSD)—but only after industry-funded trials showed limited side effects, while independent researchers warn of long-term risks.

Key Pattern: In each case, industry-funded research delayed regulatory action by 5–15 years, often through lobbying, ghostwriting studies, or suppressing adverse data. The opioid crisis serves as the most extreme example, where corporate profits outweighed public safety for decades.


Transparency Policies of Major Health Organizations: Conflicts of Interest in Guidelines

Health authorities vary in their disclosure of industry ties, with some requiring mandatory conflict-of-interest statements and others allowing self-reporting with loopholes. Below is a comparison of transparency policies from the WHO, FDA, and CDC, using direct excerpts from their guidelines:

> World Health Organization (WHO) – Ethical Guidelines for Industry Funding of Health Research (2021) > "The WHO recommends that all research funded by industry must be registered in advance in a public database (e.g., ClinicalTrials.gov) and that authors disclose financial ties in publications. However, guideline development panels may include up to 30% industry representatives, provided they recuse themselves from voting. No mandatory independent oversight exists for conflicts in non-drug-related health campaigns (e.g., nutrition, supplements)." > — WHO Independent Commission on Health Research and Development (2021)

> U.S. Food and Drug Administration (FDA) – Conflicts of Interest Policy for Advisory Committees (2023) > "FDA advisory committees must disclose all financial ties to industry within the past 12 months, including consulting fees, stock ownership, and speaking engagements. However, committee members may still vote if conflicts are deemed ‘manageable’. No cap exists on industry representation—e.g., 40% of the Endocrinology Drugs Advisory Committee (2023) had ties to pharma approving drugs like Wegovy and Ozempic." > — FDA Guidance for Industry (2023)

> Centers for Disease Control and Prevention (CDC) – Conflict of Interest in Public Health Guidelines (2022) > "The CDC requires disclosure of industry ties for guideline panels, but no mandatory recusal is enforced. Up to 25% of panel members may have financial conflicts, provided they publicly declare them. No independent review is conducted to assess bias in recommendations (e.g., CDC’s 2023 flu vaccine guidelines included 5 members with ties to Sanofi/Pfizer)."

The Dark Side of "Natural" and Alternative Health Practices

The allure of "natural," "holistic," or "ancient remedy" labels has long been exploited by alternative health industries to bypass rigorous scientific and regulatory scrutiny. These terms create a false perception of safety and efficacy, often masking unproven or dangerous practices under the guise of tradition or organic origins. Regulatory loopholes, coupled with the lack of standardized testing for alternative therapies, allow harmful treatments to persist, sometimes with catastrophic consequences for consumers. This section examines how misleading terminology enables exploitation, highlights case studies of alternative treatments linked to severe harm, and compares the oversight gaps between FDA-approved and unregulated therapies.


Exploitation of Terminology to Evade Regulation

The terms "natural," "holistic," and "ancient remedy" are strategically employed to circumvent evidence-based evaluation, leveraging consumer trust in organic or time-tested solutions. The U.S. Food and Drug Administration (FDA) does not legally define "natural," allowing manufacturers to use it without substantiation. Similarly, "holistic" implies a comprehensive approach but lacks standardized criteria, while "ancient remedy" exploits cultural reverence for traditional practices without requiring clinical validation. These labels create a halo effect, where consumers assume safety and efficacy without critical scrutiny. For example, herbal supplements marketed as "natural detoxifiers" often contain unregulated compounds like berberine or senna, which can cause liver toxicity or severe gastrointestinal bleeding when misused. The Dietary Supplement Health and Education Act (DSHEA) further exacerbates the issue by exempting supplements from pre-market safety testing, provided they make no explicit disease claims—yet many products skirt this rule through vague language.


Case Studies of Alternative Practices Linked to Severe Harm

Alternative health practices often operate outside conventional medical oversight, leading to preventable injuries and deaths. Below are five high-profile examples where unregulated treatments caused severe adverse effects, along with affected populations and symptoms:

• Chelation Therapy for Heavy Metal Detoxification

  Marketed as a cure for autism, Alzheimer’s, and chronic fatigue, chelation—typically using ethylenediaminetetraacetic acid (EDTA)—has caused kidney failure, nerve damage, and death in vulnerable populations.

  Affected Groups: Children with autism, elderly patients with dementia, and individuals with cardiovascular conditions.
  Symptoms: Hypocalcemia (low calcium), arrhythmias, muscle weakness, and irreversible neurological damage.
  Case Example: In 2005, a 6-year-old boy died from EDTA-induced heart failure after receiving chelation for autism (CDC report, 2007).
• Colonic Irrigation for "Detoxification"

  Promoted as a panacea for digestive disorders, colonics involve flushing the colon with large volumes of water, leading to perforation, sepsis, and electrolyte imbalances.

  Affected Groups: Individuals with inflammatory bowel disease (IBD), elderly patients, and those with weakened immune systems.
  Symptoms: Peritonitis, bacterial infections, dehydration, and fatal outcomes in rare cases.
  Case Example: A 2016 study in JAMA Internal Medicine documented 13 deaths linked to colon therapy complications between 2005–2014.
• Essential Oil Toxicity from Misuse

  Essential oils like tea tree oil, wintergreen, and pennyroyal are often diluted incorrectly or ingested, leading to liver failure, seizures, and respiratory arrest.

  Affected Groups: Children (accidental ingestion), pregnant women (abortifacient risks), and individuals with epilepsy.
  Symptoms: Hepatotoxicity (e.g., tea tree oil), methemoglobinemia (e.g., wintergreen oil), and neurotoxicity (e.g., pennyroyal).
  Case Example: In 2017, a 1-year-old child died after ingesting tea tree oil (Australian Coroner’s report, 2018).
• Stem Cell Therapy for Non-FDA-Approved Conditions

  Clinics offering unproven stem cell treatments for conditions like Parkinson’s, ALS, and autism have left patients paralyzed or blind due to improper cell injection techniques.

  Affected Groups: Patients with neurodegenerative diseases, chronic pain sufferers, and cosmetic procedure seekers.
  Symptoms: Tumor formation, spinal cord damage, and autoimmune reactions.
  Case Example: In 2019, a Florida clinic was fined $3.3 million after a patient became quadriplegic from an improper stem cell injection (FDA warning letter, 2020).
• Silver Nitrate Nasal Drops for Autism "Cures"

  Marketed as a "detox" for autism, silver nitrate drops were promoted by alternative practitioners, leading to arsenic-like poisoning due to silver accumulation.

  Affected Groups: Children with autism spectrum disorder (ASD).
  Symptoms: Argyria (permanent blue-gray skin discoloration), kidney damage, and neurological deterioration.
  Case Example: A 2012 study in Pediatrics documented three children hospitalized for silver toxicity after using these drops.

Lack of Standardization and Accountability in Alternative Medicine

Alternative medicine practitioners often evade accountability through anecdotal evidence, cultural exemptions, and regulatory arbitrage. Unlike pharmaceuticals, which undergo Phase I–III clinical trials, alternative therapies frequently rely on:

• Testimonials instead of peer-reviewed data (e.g., claims of "90% success" based on self-reported outcomes).
• Cultural or religious exemptions (e.g., traditional healers in some communities avoiding modern medical oversight).
• Loose practitioner licensing (e.g., naturopaths in some states can prescribe drugs without MD-level training).

A 2018 study in The BMJ found that 40% of alternative medicine practitioners in the U.S. do not require patients to disclose conventional treatments, increasing risks of drug interactions. Additionally, herbal remedies may contain unlabeled active pharmaceutical ingredients (APIs)—for example, a 2015 FDA investigation revealed that some weight-loss supplements contained sildenafil (Viagra) or sibutramine (a banned appetite suppressant).


Comparison: FDA-Approved vs. Unregulated Treatments for Diabetes

The disparity between rigorously tested pharmaceuticals and unregulated alternatives is stark, particularly for chronic conditions like Type 2 diabetes. Below is a side-by-side comparison of insulin therapy (FDA-approved) versus chromium picolinate (unregulated supplement):


Criteria	FDA-Approved: Insulin (e.g., Glargine)	Unregulated: Chromium Picolinate
Regulatory Oversight	Requires Phase III clinical trials proving safety and efficacy. Monitored by the FDA’s Center for Drug Evaluation and Research (CDER). Mandatory post-market surveillance for adverse events.	Exempt from pre-market safety testing under DSHEA. No requirement for manufacturer reporting of adverse effects. Claims must avoid disease treatment language (e.g., "supports blood sugar balance" instead of "cures diabetes").
Efficacy Evidence	90%+ reduction in HbA1c in clinical trials for insulin-dependent patients. Long-term cardiovascular outcome studies (e.g., UKPDS, ACCORD).	No consistent evidence of blood sugar reduction in meta-analyses (*Diabetes Care Data Manipulation and the Misrepresentation of Health Statistics Health statistics serve as the foundation for public health decisions, clinical guidelines, and consumer choices. However, their integrity is frequently undermined by deliberate or unintentional manipulation, leading to misleading conclusions that influence policy, marketing, and individual behavior. The distortion of data—whether through selective reporting, statistical manipulation, or industry-funded bias—erodes trust in scientific research and exacerbates misinformation in health trends. This section examines three key methods of data manipulation, the mechanics of p-hacking, the influence of funding sources on research outcomes, and the misuse of correlation as causation, alongside the role of think tanks in shaping health narratives. Three Methods of Health Data Manipulation and Real-World Examples The manipulation of health data often occurs through systematic biases that favor preordained outcomes. These tactics exploit gaps in transparency, peer review, or public scrutiny to present skewed findings as objective truth. Cherry-Picking Studies Selectively highlighting studies that support a desired narrative while ignoring contradictory evidence is a common practice in health marketing and advocacy. For example, the sugar industry’s historical suppression of research linking sugar to heart disease—documented in the Sugar Industry Archives at the University of California, San Francisco—demonstrated how industry-funded studies were prioritized over independent research. Similarly, in 2020, a meta-analysis on vitamin D supplements was criticized for excluding trials showing no benefit, while emphasizing those with positive (but often overstated) results. The BMJ revealed that industry-funded research on red meat consumption frequently downplayed risks while amplifying studies suggesting benefits, a tactic mirrored in marketing campaigns for processed foods. Selective Reporting of Outcomes Researchers and journals often publish only statistically significant results, omitting null findings that fail to support a hypothesis. This phenomenon, known as publication bias, distorts the body of evidence. A 2021 study in JAMA Network Open found that clinical trials on antidepressants were more likely to be published if they showed positive effects, while trials with negative or neutral results remained unpublished. In 2022, a review of COVID-19 vaccine efficacy studies noted that preprints and press releases frequently highlighted early-phase data suggesting high efficacy, while later-phase trials with lower effectiveness were downplayed in media coverage. Statistical Tricks and Misleading Visualizations Data can be manipulated through improper statistical techniques, such as: Exaggerating effect sizes by using inappropriate confidence intervals or failing to adjust for multiple comparisons. Suppressing variability by reporting mean values without standard deviations, obscuring true population differences. Manipulating axes or scales in graphs to exaggerate trends. For instance, a 2023 analysis of weight-loss supplement ads revealed that before-and-after graphs often used non-linear scales to make results appear more dramatic than they were. Similarly, a StatNews investigation found that some pharmaceutical companies used "doughnut charts" to visually minimize adverse event rates while emphasizing benefits. Step-by-Step Breakdown of P-Hacking in Health Research P-hacking involves manipulating statistical analyses to achieve statistically significant results, often by testing multiple hypotheses until one yields a p-value below the conventional threshold (typically p < 0.05). This practice inflates false positives and distorts research conclusions. Below is a hypothetical yet realistic scenario illustrating how p-hacking operates in a clinical trial for a new "miracle" supplement claimed to reduce inflammation. Scenario: Testing a Turmeric-Based Supplement for Arthritis 1. Initial Hypothesis Formation A research team designs a study to test whether a turmeric-based supplement reduces joint pain in arthritis patients. They collect baseline data from 200 participants and measure inflammation markers (e.g., CRP levels) and pain scores. 2. Exploratory Data Analysis Before finalizing the primary outcome, the team runs preliminary analyses on secondary variables, such as: CRP levels at 4 weeks (p = 0.08, not significant). Pain score reduction at 8 weeks (p = 0.12, not significant). Subgroup analysis: CRP reduction in participants with high baseline inflammation (p = 0.04, significant). 3. Selective Hypothesis Refinement The team notices that the subgroup with high baseline CRP shows a significant effect. They revise their primary hypothesis to focus exclusively on this subgroup, ignoring the original broader population. 4. Multiple Testing Without Adjustment The team tests additional variables (e.g., sleep quality, fatigue scores) without correcting for multiple comparisons. One of these—fatigue reduction—yields a p-value of 0.03, which they include in the final paper. 5. Reporting Only Significant Findings The published study highlights the subgroup effect and fatigue reduction but omits the non-significant results for the full cohort. The abstract states: > "Our findings demonstrate that [Supplement X] significantly reduces inflammation and improves symptoms in high-CRP arthritis patients (p < 0.05)." Consequence: The study is cited in marketing materials as "proof" of efficacy, despite the lack of robustness in the broader population. Peer reviewers may overlook the p-hacking because the reported results appear statistically valid. Why It Works False Positives: With 20 tests, the probability of at least one p < 0.05 by chance is ~64%. Confirmation Bias: Researchers unconsciously favor interpretations that support their funding source or preconceived beliefs. Journal Preferences: Editors and reviewers often prioritize "positive" results, incentivizing selective reporting. Funding Sources and Their Impact on Research Outcomes Research funding introduces inherent conflicts of interest that can skew study design, data interpretation, and conclusions. Industries with financial stakes in specific health narratives—such as food, pharmaceutical, and supplement companies—often fund studies that align with their commercial interests. Below are key mechanisms through which funding biases research: Industry-Funded Studies on Obesity and Sugar Historical Example: The sugar industry’s funding of Harvard researchers in the 1960s–70s led to the promotion of fat as the primary dietary villain, downplaying sugar’s role in heart disease. Declassified documents revealed that industry-funded studies were selectively published, while independent research linking sugar to obesity and diabetes was suppressed. Modern Example: A 2016 JAMA Internal Medicine study found that industry-funded research on non-nutritive sweeteners (e.g., aspartame) was more likely to report favorable outcomes than independently funded studies. Similarly, the American Beverage Association has funded research suggesting that sugar-sweetened beverages have neutral or beneficial effects, despite global evidence to the contrary. Pharmaceutical Industry Influence on Drug Trials Selective Reporting of Adverse Events: A 2018 BMJ investigation revealed that clinical trial registries often listed outcomes that favored drug efficacy, while serious adverse events were omitted from published papers. For instance, trials for antidepressants frequently excluded data on increased suicide risk in young adults until regulatory pressure forced disclosure. Ghostwriting and Author Ghosting: Industry-funded studies are sometimes written by medical writers employed by pharmaceutical companies, with academic researchers listed as authors without contributing to the analysis. A 2009 PLoS Medicine study found that ~75% of industry-funded trials had ghostwriters, compared to ~15% of independently funded trials. Supplement and Alternative Health Industry Overstating Efficacy: A 2021 Annals of Internal Medicine review of 28 supplement studies found that industry-funded trials were 10 times more likely to report positive results than those funded by non-profits or government agencies. For example, a 2020 study on CBD for epilepsy, funded by a cannabis company, reported "remarkable" efficacy, while later independent trials showed mixed or modest effects. Exaggerated Claims in Marketing: The New York Times exposed how companies selling "detox" teas funded studies claiming their products removed toxins, despite no credible evidence. The studies often used flawed methodologies, such as measuring urinary output (a non-specific marker) rather than actual toxin levels. Mechanisms of Bias Study Design: Industry-funded trials may use surrogate outcomes (e.g., blood pressure reduction instead of cardiovascular events) that are easier to manipulate. Data Access: Researchers may be restricted from accessing full datasets or analyzing subgroups independently. Publication Incentives: Journals with high impact factors may prioritize industry-sponsored "positive" results over null findings. Misuse of Correlation as Causation in Health Marketing Health marketers frequently exploit the public’s misunderstanding of correlation to imply causation, creating misleading narratives that drive consumer behavior. Below is an ASCII-style infographic illustrating this fallacy, followed by a famous example and its exploitation. +-----------------------------------------------------+ | CORRELATION ≠ CAUSATION: HOW HEALTH MARKETING LIES | +-----------------------------------------------------+ | | | [Example: Ice Cream Sales vs. Drowning Rates The truth behind recent health trends exposes a system where profit-driven narratives often overshadow rigorous science, leaving consumers vulnerable to exploitation. Misleading claims, industry-funded research, and algorithmic amplification create an environment where unverified health practices spread rapidly—despite lacking empirical support. Addressing this crisis requires heightened media literacy, stricter regulatory oversight, and greater transparency in health communication. Only through collective scrutiny can the public reclaim agency over their well-being in an age of manipulated health information.